Table 4.
Relationships of the NKG2D gene polymorphisms with EULAR responses to adalimumab and etanercept at 12th week of the therapy
| ADA | ETA | |||
|---|---|---|---|---|
| No Response (Number (%)) | Good/Moderate Response (Number (%)) | No Response (Number (%)) | Good/Moderate Response (Number (%)) | |
| NKG2D rs1049174 | ||||
| C | 10 (71.4%) | 103 (64.4%) | 13 (81.3%) | 153 (66.5%) |
| G | 4 (28.6%) | 57 (35.6%) | 3 (18.8%) | 77 (33.5%) |
| CC | 4 (57.1%) | 28 (35.0%) | 6 (75%) | 50 (43.5%) |
| CG | 2 (28.6%) | 47 (58.8%) | 1 (12.5%) | 53 (46.1%) |
| GG | 1 (14.3%) | 5 (6.3%) | 1 (12.5%) | 12 (10.4%) |
| NKG2D rs2255336 | ||||
| A | 2 (14.3%) | 34 (21.3%) | 0 (0%) a | 57 (24.8%) a |
| G | 12 (85.7%) | 126 (78.8%) | 16 (100%) a | 173 (75.2%) a |
| AA | 0 (0%) | 3 (3.8%) | 0 (0%) | 8 (7.0%) |
| AG | 2 (28.6%) | 28 (35.0%) | 0 (0%) | 41 (35.7%) |
| GG | 5 (71.4%) | 49 (61.3%) | 8 (100%) b | 66 (57.4%) b |
a: p-value = 0.027, OR = 0.00, 95%CI (0.00-0.82); b: GG vs. AA+AG, p-value = 0.021, OR = ∞, 95%CI (1.19–∞); OR: odds ratio; 95% CI: 95% confidence interval; ADA: adalimumab; ETA: etanercept EULAR: European League Against Rheumatism response criteria; percentages calculated in regard to a total number of patients in a given responders group.